Introduction and discussion by Daniel Benamouzig and Henri Bergeron, (directors of LIEPP's "Health Policy" research group)
Wednesday, 28th May 2014, 10h-12h
28 rue des Saints Pères
An article in the JDD mentions a rapport written by Daniel Benamouzig (CSO/CNRS), co-director of LIEPP's "health policy research group", on the drug Lucentis.
Daniel Benamouzig, co-director of LIEPP's "health policy" research group has co-authored, with Virginie Gimbert an artic
Politiques du handicap
LIEPP - Sciences Po27, rue Saint-Guillaume 75337 Paris Cedex 07 Tel. : 01 45 49 83 email@example.com